Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.
Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.